STOCK TITAN
  1. Home
  2. Sec-filings
  3. RENB
  4. [PRE 14A] Renovaro Inc. Preliminary Proxy Statement

[PRE 14A] Renovaro Inc. Preliminary Proxy Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
PRE 14A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock RENB logo
Renovaro

NASDAQ:RENB

RENB Rankings

#5283 Ranked by Market Cap
N/A Ranked by Dividends

RENB Latest News

Sep 4, 2025
Lunai Bioworks Inc. Retains American Defense International
Aug 27, 2025
Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics
Aug 8, 2025
Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks
Jul 28, 2025
Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector
Jul 17, 2025
Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

RENB Latest SEC Filings

Sep 5, 2025
[8-K] Renovaro Inc. Reports Material Event
Aug 26, 2025
[8-K] Renovaro Inc. Reports Material Event
Aug 6, 2025
[8-K] Renovaro Inc. Reports Material Event
Jul 30, 2025
[DEF 14A] Renovaro Inc. Definitive Proxy Statement
Jul 25, 2025
[8-K] Renovaro Inc. Reports Material Event

RENB Stock Data

49.28M
146.15M
36.71%
12.18%
0.34%
Biotechnology
Pharmaceutical Preparations
Link
United States
SUITE 906 LOS ANGELES